Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).
Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.
Orchestra BioMed Holdings Insider Eric S. Fain Buys $100K of Stock
Eric S. Fain bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 119,630 (+20.1%).
Orchestra BioMed Holdings Insider David Pacitti Buys $100K of Stock
David Pacitti bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 74,750 (+36.5%).
Orchestra BioMed Holdings Insider David P. Hochman Buys $25K of Stock
David P. Hochman bought 5,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $25K in total on Nov 9, 2026. Shares held after the trade: 437,916 (+1.2%).
Orchestra BioMed closed an underwritten public offering of 17,250,000 shares of common stock, which included the full exercise of the underwriters' over-allotment option. The offering was priced at $5.00 per share, generating gross proceeds of approximately $86.3 million. The company intends to use the funds to support its AVIM Therapy and Virtue SAB clinical programs, including the BACKBEAT global pivotal trial.
Orchestra BioMed Holdings Insider Darren Sherman Sells $86.1K of Stock
Darren Sherman sold 15,000 shares of Orchestra BioMed Holdings, Inc. at $5.74 a share, worth $86.1K in total on Nov 2, 2026. Shares held after the trade: 1,104,402 (-1.3%).